AMAG Pharmaceuticals, Inc. (AMAG)
(Delayed Data from NSDQ)
$11.57 USD
+0.34 (3.03%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.57 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.57 USD
+0.34 (3.03%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.57 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
AMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook
by Zacks Equity Research
AMAG Pharmaceuticals' (AMAG) earnings surpassed estimates but missed revenues in the third quarter of 2017.
AMAG Pharmaceuticals (AMAG) Down 6.6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reported earnings about a month ago. What's next for the company? We take a look at earnings estimates for some clues.
AMAG's Filing for Feraheme's Label Expansion Accepted by FDA
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) announced that the FDA accepted its submission for the label expansion of Feraheme (ferumoxytol) and has set an action date of Feb 2, 2018.
AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG) posted narrower-than-expected loss and slightly beat revenue estimates in Q2.
Spark Therapeutics (ONCE) Worth a Look: Stock Gains 5.7%
by Zacks Equity Research
Spark Therapeutics, Inc. (ONCE) shares rose above 5% in the last trading session.
AMAG Pharmaceuticals Focuses on Product Development & Buyouts
by Zacks Equity Research
We issued an updated report on AMAG Pharmaceuticals, Inc. (AMAG) on Jul 4.
Why Is AMAG Pharmaceuticals (AMAG) Down 15.6% Since the Last Earnings Report?
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alpha & Omega Semiconductor, AMAG Pharmaceuticals and Trade Desk highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Alpha & Omega Semiconductor, AMAG Pharmaceuticals and Trade Desk highlighted as Zacks Bull and Bear of the Day
Bear of the Day: AMAG Pharmaceuticals (AMAG)
by Brian Hamilton
Licensing expenses, increased SG&A, and limited market share expansion are weighing this stock down.
What Makes AMAG Pharmaceuticals (AMAG) a Strong Sell?
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
AMAG Pharma (AMAG) Incurs Loss in Q1, Revenues Rise Y/Y
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG) reported adjusted earnings of 99 cents per share in the first quarter of 2017 compared with earnings of 68 cents in the year-ago quarter
AMAG Files for FDA Approval of Subcutaneous Form of Makena
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for the subcutaneous auto-injector form of its marketed drug Makena in the U.S.
TherapeuticsMD Falls on Likely Delay in TX-004HR Approval
by Zacks Equity Research
Shares of TherapeuticsMD, Inc. (TXMD) have declined almost 25% since Monday when it received a letter from the FDA identifying deficiencies in the new drug application (NDA) for its dyspareunia drug, TX-400HR filed last July
5 Toxic Stocks to Get Rid Of or Play Short to Make Gains
by Zacks Equity Research
Exaggerated price of toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacuna.
AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG) reported adjusted earnings of $1.36 per share in the fourth quarter of 2016, up from $1.04 in the year ago quarter.
Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report fourth-quarter 2016 results on Feb 16, before the opening bell.
Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report fourth-quarter and full-year 2016 results on Feb 16.
Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?
by Zacks Equity Research
Perrigo Company plc (PRGO) is expected to report fourth-quarter 2016 results this month. Perrigo has a mixed track record as the company beat expectations in two of the last four quarters and missed the same in the other two.
Teva (TEVA) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) will be reporting fourth-quarter 2016 and full-year earnings on Feb 13, before the market opens.
Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Gilead Sciences Inc. (GILD ) is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes.
AMAG Down Despite Positive Data on Makena Auto-Injector
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) announced positive top-line results from its pharmacokinetic (PK) study on Makena, subcutaneous auto-injector.
GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?
by Zacks Equity Research
GW Pharmaceuticals plc (GWPH) is scheduled to report first-quarter fiscal 2017 results on Feb 7, before the opening bell.
Is AMAG Pharmaceuticals (AMAG) A Good Value Pick?
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder
by Zacks Equity Research
AMAG (AMAG) announced that it has entered into an agreement with Palatin (PTN) for the exclusive U.S. rights to develop and commercialize Rekynda.
New Strong Sell Stocks for January 9th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday